US Patent Issued to ALNYLAM PHARMACEUTICALS on Dec. 23 for "Compositions and methods for silencing UGT1a1 gene expression" (Massachusetts Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,699, issued on Dec. 23, was assigned to ALNYLAM PHARMACEUTICALS INC. (Cambridge, Mass.).

"Compositions and methods for silencing UGT1a1 gene expression" was invented by Donald Foster (Attleboro, Mass.) and James McIninch (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the UGT1a1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of UGT1a1."

The patent was filed on Oct. 2, 2020, under Application No. 17/765,080.

*For further information, including images, charts and tables, please visit: http://patft.uspto.g...